CA2564341A1 — Transdermal delivery system for use with basic permeation enhancers
Assigned to Dermatrends Inc · Expires 2005-10-27 · 21y expired
What this patent protects
The present invention includes transdermal delivery systems having a polymeric active agent reservoir fabricated from an admixture of polyisobutylene and an insoluble hydrophilic polymer in powdered form, which provide numerous advantages in the transdermal delivery of active age…
USPTO Abstract
The present invention includes transdermal delivery systems having a polymeric active agent reservoir fabricated from an admixture of polyisobutylene and an insoluble hydrophilic polymer in powdered form, which provide numerous advantages in the transdermal delivery of active agents using basic enhancer compositions. For example, the systems of the invention provide for (1) increased permeation of the active agent through the skin, (2) an improved capability of extracting the active agent and enhancer from the transdermal systems, (3) enhanced structural integrity, (4) good chemical stability, (5) reduced phase separation, and (6) decreased cold flow.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.